Copyright investors
On Wednesday, Illumina (ILMN) earned an upgrade to its Relative Strength (RS) Rating, from 70 to 74. This exclusive rating from Investor's Business Daily measures share price action with a 1 (worst) to 99 (best) score. The score shows how a stock's price movement over the last 52 weeks compares to all the other stocks in our database. Over 100 years of market history reveals that the best-performing stocks typically have an 80 or higher RS Rating as they launch their largest runs. See if Illumina can continue to show renewed price strength and hit that benchmark. Illumina is now considered extended and out of buy range after clearing a 111.00 buy point in a first-stage consolidation. See if the stock forms a new pattern or follow-on buying opportunity like a three-weeks tight or pullback to the 50-day or 10-week moving average. While EPS growth declined last quarter from 231% to 18%, the top line rose 0%, up from -5% in the prior report. The company earns the No. 5 rank among its peers in the Medical-Research Equipment/Services industry group. Medpace Holdings (MEDP) is the top-ranked stock within the group. This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
